scholarly journals Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell Lines

2016 ◽  
Vol 7 (10) ◽  
pp. 1295-1310 ◽  
Author(s):  
Radosław Januchowski ◽  
Monika Świerczewska ◽  
Karolina Sterzyńska ◽  
Karolina Wojtowicz ◽  
Michał Nowicki ◽  
...  
Oncotarget ◽  
2017 ◽  
Vol 8 (30) ◽  
pp. 49944-49958 ◽  
Author(s):  
Radosław Januchowski ◽  
Karolina Sterzyńska ◽  
Piotr Zawierucha ◽  
Marcin Ruciński ◽  
Monika Świerczewska ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Radosław Januchowski ◽  
Karolina Wojtowicz ◽  
Patrycja Sujka-Kordowska ◽  
Małgorzata Andrzejewska ◽  
Maciej Zabel

Ovarian cancer is the leading cause of death among gynaecological malignancies. Multiple drug resistance makes cancer cells insensitive to chemotherapy. In this study, we developed six primary ovarian cancer cell lines (W1MR, W1CR, W1DR, W1VR, W1TR, and W1PR) resistant to drugs such as methotrexate, cisplatin, doxorubicin, vincristine, topotecan, and paclitaxel. A chemosensitivity assay MTT test was performed to assess drug cross-resistance. Quantitative real-time polymerase chain reaction and Western blot were also performed to determine mRNA and protein expression of genes involved in chemoresistance. We observed high cross-resistance to doxorubicin, vincristine, and paclitaxel in the cell lines resistant to these agents. We also found a significant correlation between resistance to these drugs and increased expression of P-gp. Two different mechanisms of topotecan resistance were observed in the W1TR and W1PR cell lines. We did not observe any correlation between MRP2 transcript and protein levels. Cell lines resistant to agents used in ovarian cancer treatment remained sensitive to methotrexate. The main mechanisms of drug resistance were due to P-gp expression in the doxorubicin, vincristine, and paclitaxel resistant cell lines and BCRP expression in the topotecan resistant cell line.


2000 ◽  
Vol 36 (15) ◽  
pp. 1984-1990 ◽  
Author(s):  
J. Holford ◽  
P.J. Beale ◽  
F.E. Boxall ◽  
S.Y. Sharp ◽  
L.R. Kelland

2019 ◽  
Vol 20 (8) ◽  
pp. 2053 ◽  
Author(s):  
Świerczewska ◽  
Sterzyńska ◽  
Wojtowicz ◽  
Kaźmierczak ◽  
Iżycki ◽  
...  

Background: Ovarian cancer is the 7th most common cancer and 8th most mortal canceramong woman. The standard treatment includes cytoreduction surgery followed bychemotherapy. Unfortunately, in most cases, after treatment, cancer develops drug resistance.Decreased expression and/or activity of protein phosphatases leads to increased signaltransduction and development of drug resistance in cancer cells. Methods: Using sensitive (W1,A2780) and resistant ovarian cancer cell lines, the expression of Protein Tyrosine PhosphataseReceptor Type K (PTPRK) was performed at the mRNA (real‐time PCR analysis) and protein level(Western blot, immunofluorescence analysis). The protein expression in ovarian cancer tissues wasdetermined by immunohistochemistry. Results: The results showed a decreased level of PTPRKexpression in ovarian cancer cell lines resistant to cisplatin (CIS), paclitaxel (PAC), doxorubicin(DOX), topotecan (TOP), vincristine (VIN) and methotrexate (MTX). Additionally, the lowerPTPRK expression was observed in Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1)positive cancer stem cells (CSCs) population, suggesting the role of PTPRK downregulation inprimary as well as acquired resistance to cytotoxic drugs. Conclusions: These results provideimportant insights into the role of PTPRK in mechanism leading to drug resistance in ovariancancer and has raised important questions about the role of imbalance in processes ofphosphorylation and dephosphorylation.


2017 ◽  
Vol 14 (1) ◽  
pp. 35-52 ◽  
Author(s):  
ISA N CRUZ ◽  
HELEN M COLEY ◽  
HOLGER B KRAMER ◽  
THUMULURU KAVITAH MADHURI ◽  
NUR A.M SAFUWAN ◽  
...  

2020 ◽  
Vol 31 (19) ◽  
pp. 195101 ◽  
Author(s):  
Mohammad A Obeid ◽  
Siti Aisya S Gany ◽  
Alexander I Gray ◽  
Louise Young ◽  
John O Igoli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document